URB597, an inhibitor of fatty acid amide hydrolase, reduces hyperalgesia in diabetic rats

Canadian Journal of Physiology and Pharmacology

Volumn 87, Issue 6, 2009, Pages 432-439

  Hasanein, Parisa ^a   Parviz, Mohsen ^b   Keshavarz, Mansoor ^b   Roohbakhsh, Ali ^c  

^a BU ALI SINA UNIVERSITY   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c RAFSANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetes; FAAH; Hyperalgesia; Neuropathy; Nociception; Rats; URB597

Indexed keywords

CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; FATTY ACID AMIDASE; FORMALDEHYDE; GLUCOSE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; BODY WEIGHT; CONTROL GROUP; CONTROLLED STUDY; DIABETIC NEUROPATHY; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HYPERALGESIA; HYPERGLYCEMIA; NEUROTRANSMISSION; NONHUMAN; PAIN; PRIORITY JOURNAL; RAT; RAT STRAIN; STREPTOZOCIN DIABETES; TAIL FLICK TEST;

AMIDOHYDROLASES; ANIMALS; BENZAMIDES; BLOOD GLUCOSE; BODY WEIGHT; CARBAMATES; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCANNABINOIDS; ENZYME INHIBITORS; HYPERALGESIA; INJECTIONS, INTRAPERITONEAL; MALE; PAIN MEASUREMENT; PAIN THRESHOLD; RATS; RATS, WISTAR; TEMPERATURE;

EID: 67449119679     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/Y09-026     Document Type: Article

References (41)

1. Abbott, F.V., Franklin, K.B., and Westbrook, R.F. 1995. The formalin test: scoring properties of the first and second phases of the pain response in rats. Pain, 60: 91-102. doi:10.1016/0304-3959(94)00095-V. PMID:7715946.
2. Agarwal, N., Pacher, P., Tegeder, I., Amaya, F., Constantin, C.E., Brenner, G.J., et al. 2007. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat. Neurosci. 10: 870-879. doi:10.1038/nn1916. PMID:17558404.
3. Calcutt, N.A., Freshwater, J.D., and Mizisin, A.P. 2004. Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor. Diabetologia, 47: 718-724. doi:10.1007/s00125-004-1354-2. PMID:15298349. (Pubitemid 38658374)
4. Ceseña, R.M., and Calcutt, N.A. 1999. Gabapentin prevents hyperalgesia during the formalin test in diabetic rats. Neurosci. Lett. 262: 101-104. doi:10.1016/S0304-3940(99)00057-9. PMID:10203241.
5. Chang, L., Luo, L., Palmer, J.A., Sutton, S., Wilson, S.J., Barbier, A.J., et al. 2006. Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br. J. Pharmacol. 148: 102-113. doi:10.1038/sj.bjp. 0706699. PMID:16501580.
6. Coderre, T.J., Fundytus, M.E., McKenna, J.E., Dalal, S., and Melzack, R. 1993. The formalin test: a validation of the weighted-scores method of behavioural pain rating. Pain, 54: 43-50. doi:10.1016/0304-3959(93)90098-A. PMID:8378102. (Pubitemid 23200570)
7. Courteix, C., Eschalier, A., and Lavarenne, J. 1993. Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain, 53: 81-88. doi:10.1016/0304-3959(93)90059-X. PMID:8316394. (Pubitemid 23137271)
8. Courteix, C., Bourget, P., Caussade, F., Bardin, M., Coudore, F., Fialip, J., and Eschalier, A. 1998. Is the reduced efficacy of morphine in diabetic rats caused by alterations of opiate receptors or of morphine pharmacokinetics? J. Pharmacol. Exp. Ther. 285: 63-70. PMID:9535995.
9. Cravatt, B.F., Demarest, K., Patricelli, M.P., Bracey, M.H., Giang, D.K., Martin, B.R., and Lichtman, A.H. 2001. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. U.S.A. 98: 9371-9376. doi:10.1073/pnas. 161191698. PMID:11470906.
10. Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.C., and Piomelli, D. 1994. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature, 372: 686-691. doi:10.1038/372686a0. PMID:7990962.
11. Doǧrul, A., Gül, H., Yildiz, O., Bilgin, F., and Güzeldemir, M.E. 2004. Cannabinoids blocks tactile allodynia in diabetic mice without attenuation of its antinociceptive effect. Neurosci. Lett. 368: 82-86. doi:10.1016/j.neulet.2004.06.060. PMID:15342139.
12. Duarte, J.M., Nogueira, C., Mackie, K., Oliveira, C.R., Cunha, R.A., and Köfalvi, A. 2007. Increase of cannabinoid CB1 receptor density in the hippocampus of streptozotocin-induced diabetic rats. Exp. Neurol. 204: 479-484. doi:10.1016/j.expneurol.2006.11.013. PMID:17222407.
13. Fegley, D., Gaetani, S., Duranti, A., Tontini, A., Mor, M., Tarzia, G., and Piomelli, D. 2005. Characterization of the fatty acid amide hydrolase inhibitor cyclohexylcarbamic acid 3-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J. Pharmacol. Exp. Ther. 313: 352-358. doi:10.1124/jpet.104.078980. PMID:15579492.
14. Forman, L.J., Estilow, S., Lewis, M., and Vasilenko, P. 1986. Streptozocin diabetes alters immunoreactive beta-endorphin levels and pain perception after 8 week in female rats. Diabetes, 35: 1309-1313. doi:10.2337/diabetes.35.12.1309. PMID:2945745. (Pubitemid 17199161)
15. Fox, A., Eastwood, C., Gentry, C., Manning, D., and Urban, L. 1999. Critical evaluation of the streptozotocin model of painful diabetic neuropathy in the rat. Pain, 81: 307-316. doi:10.1016/S0304-3959(99)00024-X. PMID:10431718. (Pubitemid 29257901)
16. Freshwater, J.D., Malmberg, A.B., and Calcutt, N.A. 2002. Elevated spinal cyclooxygenase and prostaglandin release during hyperalgesia in diabetic rats. Diabetes, 51: 2249-2255. doi:10.2337/diabetes.51.7.2249. PMID:12086957. (Pubitemid 34729032)
17. Gupta, M., Singh, J., Sood, S., and Arora, B. 2003. Mechanism of antinociceptive effect of nimodipine in experimental diabetic neuropathic pain. Methods Find. Exp. Clin. Pharmacol. 25: 49-52. doi:10.1358/mf.2003.25.1.772547. PMID:12690707.
18. Gutierrez, T., Nackley, A.G., Neely, M.H., Freeman, K.G., Edwards, G.L., and Hohmann, A.G. 2003. Effects of neurotoxic destruction of descending noradrenergic pathways on cannabinoid antinociception in models of acute and tonic nociception. Brain Res. 987: 176-185. doi:10.1016/S0006-8993(03)03324-9. PMID:14499961. (Pubitemid 37281432)
19. Hasanein, P., Parviz, M., Keshavarz, M., Javanmardi, K., Mansoori, M., and Soltani, N. 2006. Oral magnesium administration prevents thermal hyperalgesia induced by diabetes in rats. Diabetes Res. Clin. Pract. 73: 17-22. doi:10.1016/j.diabres.2005.12.004. PMID:16417942.
20. Hohmann, A.G., and Suplita, R.L. 2006. Endocannabinoid mechanisms of pain modulation. AAPS J. 8: E693-E708. doi:10.1208/aapsj080479. PMID:17233533. (Pubitemid 44867027)
21. Hohmann, A.G., Suplita, R.L., Bolton, N.M., Neely, M.H., Fegley, D., Mangieri, R., et al. 2005. An endocannabinoid mechanism for str ess-induced analgesia. Nature, 435: 1108-1112. doi:10.1038/nature03658. PMID:15973410. (Pubitemid 40910518)
22. Jayamanne, A., Greenwood, R., Mitchell, V.A., Aslan, S., Piomelli, D., and Vaughan, C.W. 2006. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br. J. Pharmacol. 147: 281-288. doi:10.1038/sj.bjp.0706510. PMID:16331291.
23. Jhaveri, M.D., Richardson, D., and Chapman, V. 2007. Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br. J. Pharmacol. 152: 624-632. doi:10.1038/sj.bjp.0707433. PMID:17704819.
24. Kathuria, S., Gaetani, S., Fegley, D., Valino, F., Duranti, A., Tontini, A., et al. 2003. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 9: 76-81. doi:10.1038/nm803. PMID:12461523.
25. Lee, J.H., and McCarty, R. 1990. Glycemic control of pain threshold in diabetic and control rats. Physiol. Behav. 47: 225-230. doi:10.1016/0031- 9384(90)90135-Q. PMID:2159159.
26. Lee, J.H., and McCarty, R. 1992. Pain threshold in diabetic rats: effects of good versus poor diabetic control. Pain, 50: 231-236. doi:10.1016/0304- 3959(92)90167-A. PMID:1408322.
27. Lichtman, A.H., Leung, D., Shelton, C.C., Saghatelian, A., Hardouin, C., Boger, D.L., and Cravatt, B.F. 2004. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J. Pharmacol. Exp. Ther. 311: 441-448. doi:10.1124/jpet.104.069401. PMID:15229230.
28. Maione, S., De Petrocellis, L., de Novellis, V., Moriello, A.S., Petrosino, S., Palazzo, E., et al. 2007. Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br. J. Pharmacol. 150: 766-781. doi:10.1038/sj.bjp.0707145. PMID:17279090.
29. Malcangio, M., and Tomlinson, D.R. 1998. A pharmacologic analysis of mechanical hyperalgesia in streptozotocin/diabetic rats. Pain, 76: 151-157. doi:10.1016/S0304-3959(98)00037-2. PMID:9696468. (Pubitemid 28304951)
30. Malmberg, A.B., Yaksh, T.L., and Calcutt, N.A. 1993. Anti-nociceptive effects of the GM1 ganglioside derivative AGF 44 on the formalin test in normal and streptozotocin-diabetic rats. Neurosci. Lett. 161: 45-48. doi:10.1016/0304-3940(93)90136-9. PMID:8255545.
31. Manning, B.H., and Franklin, K.B. 1998. Morphine analgesia in the formalin test: reversal by microinjection of quaternary naloxone into the posterior hypothalamic area or periaqueductal gray. Behav. Brain Res. 92: 97-102. doi:10.1016/S0166-4328(97)00130-7. PMID:9588689.
32. Mao, J., Price, D.D., Hayes, R.L., Lu, J., and Mayer, D.J. 1992. Intrathecal GM1 ganglioside and local nerve anesthesia reduce nociceptive behaviors in rats with experimental peripheral mononeuropathy. Brain Res. 584: 28-53. doi:10.1016/0006-8993(92)90874-9. PMID:1325247.
33. McKinney, M.K., and Cravatt, B.F. 2005. Structure and function of fatty acid amide hydrolase. Annu. Rev. Biochem. 74: 411-432. doi:10.1146/annurev. biochem.74.082803.133450. PMID:15952893.
34. Obrosova, I.G. 2003. Update on the pathogenesis of diabetic neuropathy. Curr. Diab. Rep. 3: 439-445. doi:10.1007/s11892-003-0005-1. PMID:14611738.
35. Piomelli, D., Tarzia, G., Duranti, A., Tontini, A., Mor, M., Compton, T.R., et al. 2006. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev. 12: 21-38. doi:10.1111/j.1527-3458.2006.00021. x. PMID:16834756. (Pubitemid 44133578)
36. Russo, R., Loverme, J., La Rana, G., Compton, T.R., Parrott, J., Duranti, A., et al. 2007. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J. Pharmacol. Exp. Ther. 322: 236-242. doi:10.1124/jpet.107.119941. PMID:17412883.
37. Tentolouris, N., Pagoni, S., Tzonou, A., and Katsilambros, N. 2001. Peripheral neuropathy does not invariably coexist with autonomic neuropathy in diabetes mellitus. Eur. J. Intern. Med. 12: 20-27. doi:10.1016/S0953-6205(00) 00128-X. PMID:11173007.
38. Ulugol, A., Karadag, H.C., Ipci, Y., Tamer, M., and Dokmeci, I. 2004. The effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic rats. Neurosci. Lett. 371: 167-170. doi:10.1016/j.neulet.2004.08.061. PMID:15519750.
39. Young, M.J., Boulton, A.J., MacLeod, A.F., Williams, D.R., and Sonksen, P.H. 1993. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia, 36: 150-154. doi:10.1007/BF00400697. PMID:8458529. (Pubitemid 23034314)
40. Zhang, F., Hong, S., Stone, V., and Smith, P.J. 2007. Expression of cannabinoid CB1 receptors in models of diabetic neuropathy. J. Pharmacol. Exp. Ther. 323: 508-515. doi:10.1124/jpet.107.128272. PMID:17702901.
41. Zurek, J.R., Nadeson, R., and Goodchild, C.S. 2001. Spinal and supraspinal components of opioid antinociception in streptozotocin induced diabetic neuropathy in rats. Pain, 90: 57-63. doi:10.1016/S0304-3959(00)00386-9. PMID:11166970. (Pubitemid 32146557)